autologous epstein-barr virus-specific cytotoxic t lymphocytes
Cell therapyexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Feb 1, 2000 (NCT00005606)
Timeline
2000s
- Jan 1, 2000
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
- Human herpesvirus 4Immunity, passive
Human herpesvirus 4 immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- autologous epstein-barr virus-specific cytotoxic t lymphocytes
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00690872 | Phase 2 | Jul 1, 2008 | Government of Singapore |
| NCT00005606 | Phase 2 | Feb 1, 2000 | National Cancer Institute (NCI), Northwestern University |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Government of Singapore | Government | 1 | 1 | 1 | 2008 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2000 |
| Northwestern University | Academic/Hospital | 1 | 1 | 1 | 2000 |
3 organizations
Page 1 / 1